IRD Opus Genetics Inc.

$IRD forming a Triangle. If we can breakout of the Triangle than ( Over 6.25 $) Calculate: high of the Triangle 7.06 -5.32= 2.74 Breakout Point 6.25 + 2.74 = 9.89$ target

$IRD Im new here and did my diligence. I found no new company financing/ATM dilution disclosure, material SEC filing, or negative LCA5/BEST1 clinical development in this check. The next scheduled BEST1 scientific presentation remains October 14. Analysts are raising targets and reiterated buy ratings. PDUFA this month for Phentolamine which already has FDA approval as RYZUMVI. Then theres the milestone payments once they get approval. Im bullish but this setup looks to good to be true.

$IRD 3 Data read in next 2 weeks include PDUFA.. You will be appreciated with this opportunity

$IRD keeps chuggin forward...when we get more traction and volume it's game on 💎💰Buy buy buy.

$IRD well looks like the $5 covered calls I sold worked out. Now use the profit to add on the gap fill then ride back up for the Oct. catalyst . Would be nice to fill that gap and take care of it before the next move.

$IRD 6.25$ IS still the Key to Close above in the next days for the bulls. To See Run to Double Digits before pdufa in october

For those following the journey, the AI overlords are taking another crack at a prediction (#3). This is what it's saying: $IRD — Oct. 17 PDUFA: Phentolamine 0.75% for presbyopia Approval odds: ~50% Modeled equity impact: +2.5% approval / −7.4% CRL Why the coin toss? Both trials hit primary + key secondary endpoints with strong statistical significance and no treatment-related SAEs. It’s also the same 0.75% formulation already approved as RYZUMVI. But the absolute efficacy is modest: ~73% of treated patients still didn't achieve the ≥3-line improvement at 12 hours, despite p<0.0001. Add a fourth-entrant market (VIZ, QLosi, VUITY) and Viatris controlling the filing, launch and prioritization, and I’m keeping it around a coin flip. Separate risk: even with approval, label breadth/duration could materially change the royalty opportunity. Downside > upside because some success is already priced in, while a CRL removes near-term royalty/milestone value, delays cash flows and increases financing pressure. Let's see what happens 👀

$IRD Admittedly I just got in here so forgive some of the forthcoming ignorance. I was briefly in the company that was subsumed by IRD (whose ticker symbol currently escapes me), but haven’t looked back in on IRD for awhile. Does anybody have theories as to why the recent price action seemed so “unenthusiastic?” I see an upcoming PDUFA date in a seemingly large TAM. It would seem this company should see a rerate after approval. Is there something going on that is not obvious to the neophytes? TIA.

$IRD Dont chase if you didnt get in pre market. continuation play. Target was 6,44. Extension (6.90-6,98). LOW VOLUME

$IRD will see if the recovers after rate news today, happy to sell majority of my holding now with a view to buying back in before October news.